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Purpose or Objective 
To investigate changes of immune-phenotyping values in 
patients treated with Stereotactic Body Radiation Therapy 
(SBRT) over the lung in order to evaluate the immune 
response after radiation therapy. 
Material and Methods 
From November 2016 to May 2018, 7 patients (p) with 7 
lung lesions were enrolled in a translational sub-study. All 
of them underwent SBRT treatment.  
Peripheral blood samples prior to the treatment for each 
patient (1month, 3 months and 6 months) were collected 
and analyzed. Peripheral mononuclear cells (PBMCs) were 
isolated from a heparinized venous blood sample by 
density gradient centrifugation. After centrifugation, 
PBMCs were collected from the plasma–Ficoll interphase 
and used for flow cytometry. 
Three panels were used:  
- Lymphocyte Phenotyping DuracloneTM, Beckman 
Coulter: CD16 Ab , CD56 Ab, CD19 Ab, CD14 Ab, CD4 Ab, 
CD8 Ab, CD3 Ab, CD45 Ab 
- Regulatory T cells DuracloneTM, BeckmanCoulter: 
CD45RA Ab, CD25 Ab, CD39 Ab, CD4 Ab, Intracellular 
FOXP3 Ab, CD3 Ab, Helios Ab, CD45 Ab 
- Myeloid Derived Supressor Cells (MDSC) DuracloneTM, 
BeckmanCoulter: CD45, HLA-DR, CD14, CD33, CD11b.  
Cell surface and intracellular staining were performed 
according to the manufacturer’s protocols. Cell 
phenotypes were evaluated using the FACS Navios system 
(BeckmanCoulter).  
 Results 
Median age was 73r (65-80). 5 Males and 2 females. 
Primary lung tumor 5 cases, 1 CRC and 1 breast primary. 
None were a candidate to undergo surgery after 
evaluation in a multidisciplinary tumor board. Locations 
were: 2p right upper lobe, 3p right inferior lobe and 2p 
right medium lobe. Following the clinical protocol doses 
delivered were 60Gy (7.5Gy x 8fr) in 3p y 50Gy (12.5Gy x 
4 fr) in 4 p. Mean follow up of 16 months r(2-
20),  1p  incomplete response, 2p in partial response 
and  4 in stable . 
 Lymphocyte Phenotyping showed that Natural Killer cells 
defined as CD56+high CD16+ , increased among the follow 
up with initial values of   0.95% to 1.38% at  6 months. 
Statistical analysis using Friedman Test (p=0.18) and 
Wilcoxon test don´t showed significant differences.  
Regulatory T cells activated defined as (CD4+-CD25+Foxp3 
+CD45RA) showed stable values during the follow up 
(baseline values 4.97% vs. 4.46% at 6 months). No 
statistical differences were detected.  
Myeloid-derived suppressor cells (MDSC) 
CD33+CD11b+CD14-, showed a tendency to lower values 
during the follow up (basal 62.6% vs 66.1%). No statistical 
significance was detected.  
Conclusion 
High doses of radiation therapy over the lung can provide 
a systemic effect detected in peripheral blood samples. 
Even the small sample size, our study shows an increase of 
stimulatory immune populations with stability or 
decreasing suppressive populations.  
 
 
